News Agency News Aggregator Journalist/Editor Broking House Others
Like IOL Chemicals, I heard that Pfizer is also having low dependency on China.... CMP 4200...
#PFIZER: The target price for Pfizer Limited has increased to ₹4,732.2 from ₹4,467.2 in the last week.
Pfizer posted fairly good results for Q3. Its recent launches and other upcoming products are likely to boost its performance.
From 4000 now 2 session.. Pfizer
Pfizer gaiNing good strenght and momentum...
Saama and Pfizer to Transform Work of Clinical Data Managers and Monitors With AI: Saama Technologies Inc. the number one AI clinical analytics platform company announced today that it signed an agreement with Pfizer Inc. to develop and deploy an…
#JustIn | Key secretaries & senior officials from health, pharma, finance, drug controller etc along with industry captains like heads of Torrent, Cadila, Dr Reddy's, Cipla, Biocon, Mylan, Lupin, Alembic pharma, Pfizer, Jubilant, Aarti Drugs, Divi's Labs to be present at the meet
Pfizer reported Q3 net profit Rs139cr (up 6.1% YoY) - expectation Rs140cr and Income Rs538cr (up 4.7% YoY) - expectation Rs565cr. #MOMarketUpdates
PFIZER Ltd Q3 net profit up YoY at Rs. 139.06 crore
Pfizer. CMP 4193 Bal as on 31.3.2019 Reserves - 3110 cr Cash & Bank bal - 2025 cr
PFIZER - Announcement under Regulation 30 (LODR)-Change in Directorate
#stockstowatch #Pfizer It is one of the world's largest pharmaceutical companies Manufacturer of Viagra Share Crashed Today Post Numbers Three Largest Fall in 10 yrs Sept 2013 -22% Jan 2008 -11% Today -9% Its Markets Valentine Gift
#PFIZER PFIZER RESULT
#3QWithCNBCTV18 | Pfizer India Q3 net profit & revenue rise on a yearly basis while EBITDA slips; margin falls more than 500 bps
#ResultsOnZB | फाइजर ने पेश किए दिसंबर तिमाही के नतीजे, कंपनी का मुनाफा बढ़कर ₹139 करोड़ हुआ > आय ₹514 करोड़ से बढ़कर ₹538 करोड़ > EBITDA ₹154 करोड़ से घटकर ₹133 करोड़ #ZBizBazaar #Pfizer
PFIZER - Unaudited Financial Results For The Quarter Ended December 31, 2019.
PFIZER - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pfizer expected to launch cancer biosimilar Trastuzumab on 15th Feb Biocon/ Mylan launched their version of Trastuzumab in Dec 2019 in US Est of arnd 6-9% market share in Biocon���s Trastuzumab in first year and 14-15% in 2nd yr Size is $2.5b with upto 4-5 cos selling the drug